Del Vecchio L, Sitia S
Divisione di Nefrologia e Dialisi, Ospedale A. Manzoni, Lecco, Italy.
G Ital Nefrol. 2009 May-Jun;26(3):347-54.
In addition to data regarding its effects on the heart, brain and blood vessels, extensive evidence has emerged about the contribution of aldosterone to kidney damage. This has mainly been studied in the setting of experimental models of salt-sensitive hypertension but has been confirmed also in other animal models. The evidence is supported by a clear causal relationship between aldosterone infusion and development of kidney damage and its reversal after aldosterone blockade. Since 2001, clinical data have been obtained on the antiproteinuric effect of aldosterone antagonists added to ACE inhibitors or angiotensin II receptor blockers. Unfortunately, the long-term findings are still scanty, except for those obtained in two one-year studies. Altogether, this therapeutic approach appears relatively safe and effective; however, larger studies on patients with a wider range of chronic kidney disease severities and longer follow-up are needed to confirm it.
除了有关醛固酮对心脏、大脑和血管影响的数据外,关于醛固酮对肾脏损害的作用也有大量证据出现。这主要是在盐敏感性高血压实验模型中进行研究的,但在其他动物模型中也得到了证实。醛固酮输注与肾脏损害的发生及其在醛固酮阻断后的逆转之间存在明确的因果关系,为这些证据提供了支持。自2001年以来,已经获得了关于在ACE抑制剂或血管紧张素II受体阻滞剂基础上加用醛固酮拮抗剂的抗蛋白尿作用的临床数据。不幸的是,除了两项为期一年的研究结果外,长期研究结果仍然很少。总体而言,这种治疗方法似乎相对安全有效;然而,需要对更广泛的慢性肾脏病严重程度患者进行更大规模的研究,并进行更长时间的随访来证实这一点。